Patents by Inventor Perry Tal

Perry Tal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDE ANALOGS AND USE OF SAME IN TREATING DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT P53 PROTEIN
    Publication number: 20230127559
    Abstract: Peptide analogs which are endowed with the property of at least partially reactivating a mutant p53 protein are provided. Also provided are uses thereof in the treatment of diseases associated with mutant p53.
    Type: Application
    Filed: March 15, 2021
    Publication date: April 27, 2023
    Inventors: Varda ROTTER, Moshe OREN, Perry TAL, Fernando ALBERICIO
  • PEPTIDES AND USE OF SAME IN THE TREATMENT OF DISEASES, DISRODERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53
    Publication number: 20220251159
    Abstract: An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382.
    Type: Application
    Filed: December 13, 2021
    Publication date: August 11, 2022
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD
    Inventors: Varda ROTTER, Moshe OREN, Perry TAL, Shay EIZENBERGER, Avi BEN-SHIMON
  • Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53
    Patent number: 11230578
    Abstract: An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: January 25, 2022
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Varda Rotter, Moshe Oren, Perry Tal, Shay Eizenberger, Avi Ben-Shimon
  • Peptides capable of reactivating p53 mutants
    Patent number: 11028127
    Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: June 8, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Moshe Oren, Varda Rotter, Perry Tal
  • PEPTIDES CAPABLE OF REACTIVATING p53 MUTANTS
    Publication number: 20200095282
    Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
    Type: Application
    Filed: December 5, 2019
    Publication date: March 26, 2020
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Moshe OREN, Varda ROTTER, Perry TAL
  • Peptides capable of reactivating p53 mutants
    Patent number: 10550152
    Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: February 4, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Moshe Oren, Varda Rotter, Perry Tal
  • PEPTIDES CAPABLE OF REACTIVATING p53 MUTANTS
    Publication number: 20190315804
    Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 17, 2019
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Moshe OREN, Varda ROTTER, Perry TAL
  • Peptides capable of reactivating p53 mutants
    Patent number: 10336789
    Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
    Type: Grant
    Filed: October 29, 2017
    Date of Patent: July 2, 2019
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Moshe Oren, Varda Rotter, Perry Tal
  • PEPTIDES AND USE OF SAME IN THE TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53
    Publication number: 20190048053
    Abstract: An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 14, 2019
    Inventors: Varda ROTTER, Moshe OREN, Perry TAL, Shay EIZENBERGER, Avi BEN-SHIMON
  • PEPTIDES CAPABLE OF REACTIVATING p53 MUTANTS
    Publication number: 20180057533
    Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
    Type: Application
    Filed: October 29, 2017
    Publication date: March 1, 2018
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Moshe OREN, Varda ROTTER, Perry TAL
  • Peptides capable of reactivating p53 mutants
    Patent number: 9856289
    Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: January 2, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Moshe Oren, Varda Rotter, Perry Tal
  • PEPTIDES CAPABLE OF REACTIVATING p53 MUTANTS
    Publication number: 20160215019
    Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
    Type: Application
    Filed: February 4, 2016
    Publication date: July 28, 2016
    Inventors: Moshe OREN, Varda Rotter, Perry Tal